Business Context and Reporting Period
Company: LifeMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 15, 2026
Principal Event: Announcement of an exclusive strategic collaboration with AT&T Services, Inc. under Item 7.01 (Regulation FD Disclosure).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a strategic partnership announcement rather than periodic financial results.
Material Changes and Strategic Developments
- Partnership Structure: LifeMD entered a Subscriber Health & Wellness Collaboration Agreement with AT&T to provide complimentary LifeMD memberships to eligible AT&T wireless and fiber customers.
- Launch Scope: The program will launch in multiple phases, starting with a limited number of states before expanding nationwide.
- Compensation Model: LifeMD will initially pay AT&T a fixed fee per lead. Subsequent compensation terms are subject to negotiation.
- Governance: A joint steering committee will oversee strategy, marketing, budget, creative, pricing, performance, and dispute resolution.
- Term: The agreement has an initial term of one year with automatic renewal for successive one-year periods, unless either party provides 90 days' written notice of non-renewal.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing contains expectations regarding launch timing, scope, pricing, patient demand, and program benefits. These are based on current assumptions and are not guarantees.
Key Risks and Contingencies:
- Commercial launch and adoption rates may differ from expectations.
- Changes in federal or state laws governing telehealth prescribing of controlled substances.
- Regulatory and compliance requirements applicable to telehealth, pharmacy, and pharmaceutical promotion.
- Standard indemnification provisions apply, subject to certain limitations.
Investor Verification Checklist
- Verify the specific states included in the initial launch phase of the AT&T collaboration.
- Monitor future filings for details on the negotiated compensation structure beyond the initial fixed fee per lead.
- Review LifeMD's most recent Form 10-K and 10-Q for detailed risk factors regarding telehealth regulation and controlled substance prescribing.
- Track the performance metrics and patient adoption rates once the program goes live to assess the partnership's financial impact.